Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two New Sides Of Cubist: Antibiotics Maker Buys Both Optimer And Trius

This article was originally published in The Pink Sheet Daily

Executive Summary

The Boston-area company will no longer rely as heavily on the antibiotic Cubicin, once it takes out its partner on a second marketed drug and, separately, a clinical-stage antibiotics company. The deals give Cubist territorial rights to Optimer’s Dificid for C. diff and Trius’s tedizolid for Gram-positive infections for $535 million and $707 million, respectively, plus CVRs.


Related Content

Cubicin Becomes Blockbuster, As Cubist Passes on Adynxx Acquisition
Cubist Pushes Trius Drug Forward As Cubicin Comes Up Short
Next Up For Cubist: A Future That Includes Optimer, Trius
Cubist’s Time To Shine: Antibiotic Specialist Acquires Optimer, Trius
Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts